Bethesda, MDNCT06157151Now EnrollingIRB Ready

Cervical Cancer Clinical Trial in Bethesda, MD

Access cutting-edge cervical cancer treatment through this phase 2 clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.

Sponsored by Precigen, Inc

Quick Self-Assessment

See if you qualify for this Bethesda location

Preparing your pre-screening questions…

Expert Care in Bethesda

Access cervical cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cervical cancer treatment provided free

Apply for This Bethesda Location

Check if you qualify for this cervical cancer clinical trial in Bethesda, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Bethesda

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Bethesda site if eligible
  4. 4Begin participation

About This Cervical Cancer Study in Bethesda

This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.

Sponsor: Precigen, Inc

Who Can Participate

Inclusion Criteria

Age 18 years and older.
Recurrent or metastatic cervical cancer (histologically or cytologically confirmed)
Must have been treated with pembrolizumab, either as monotherapy or in combination, for atleast 6 weeks.
Subjects must have histologically or cytologically confirmed HPV positive disease
Measurable disease that can be accurately measured by RECIST v1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy ≥ 12 weeks from the time of enrollment.
Must have adequate organ function
Negative serum pregnancy test. Women of child-bearing potential (WOCBP) must agree to use adequate contraception prior to study entry and for at least 6 months following completion of study treatment.
All patients must have the ability to understand and willingness to sign a written informed consent.

Exclusion Criteria

Prior chemotherapy, targeted therapy within 14 days; monoclonal antibody within 4 weeks; unresolved AEs.
Immunodeficiency, active autoimmune disease on immunosuppression, or immunosuppressive therapy within 7 days. HIV eligible with disease control.
Active hepatitis B (HBsAg+) or hepatitis C (HCV RT-PCR+) within 30 days of enrollment.
History of non-infectious pneumonitis or interstitial lung disease.
History of endocrine autoimmune disease (exceptions: treated Graves' disease; hypothyroidism on replacement).
Live vaccine within 30 days prior to first dose.
Patients with presence of other active malignancy within 1 year prior to study entry
Known Central Nervous System (CNS) disease
Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
Known history of active tuberculosis (TB, Bacillus tuberculosis).
Pregnant and lactating women are excluded from this study.
Patients with a history of solid organ transplant.
Patients currently participating in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of study treatment.
Patients, who in the opinion of the investigator, may not be able to comply with the monitoring requirements of the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bethesda?

Yes, this clinical trial (NCT06157151) has an active research site in Bethesda, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cervical Cancer Treatment Options in Bethesda, MD

If you're searching for cervical cancer treatment options in Bethesda, MD, this clinical trial (NCT06157151) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bethesda research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced cervical cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cervical cancer clinical trials near you to find additional studies recruiting in your area.

More Cervical Cancer Trials in Bethesda, MD

See all cervical cancer clinical trials recruiting in Bethesda — not just this study.

Browse Cervical Cancer Trials in Bethesda →

Browse More Trials by Condition

Cervical Cancer TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Bethesda?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Bethesda, MD